Tilray Brands (TLRY) Stock: Buy, Sell, or Hold?
TLRY - Tilray Brands, Inc. Common Stock
$2.82
-0.11 (-3.86%)
▼
5d:
-7.34%
30d:
-30.79%
90d:
-30.1%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 08, 2026
0d
Get Alerted When TLRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TLRY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: TLRY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: TLRY is currently trading at $2.82, which is considered oversold relative to its 30-day fair value range of $3.19 to $4.05. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.5) compared to its historical average (201.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLRY is in a strong uptrend. The price is currently testing key support at $2.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.61 (+91.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TLRY is in a strong uptrend. The price is currently testing key support at $2.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.61 (+91.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.19 -
$4.05
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding TLRY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 91.5% below Wall St target ($5.61)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
- CAUTION: 5-day price weakness (-7.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.19 -
$4.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.80
Resistance Level
$3.56
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.49
Wall Street Target
$5.61
(+91.5%)
Revenue Growth (YoY)
22.7%
Profit Margin
-17.1%
PE vs Historical
-7.5 vs 201.6
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 2:44 PM ET
Data refreshes hourly during market hours. Next update: 3:44 PM
Data refreshes hourly during market hours. Next update: 3:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
Advanced TLRY Option Strategies
Professional options setups generated by AI based on today's TLRY price and gamma walls.
